CT-P10 (Truxima™) is the first biosimilar of the reference monoclonal anti-CD20 antibody rituximab. It is approved for use in all indications for which reference rituximab is approved, including follicular lymphoma (FL), diffuse large B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rhe …

We evaluated real-world effectiveness and safety of CT-P10 (Truxima ®) compared with originator rituximab in diffuse large B-cell lymphoma (DLBCL) treatment. Before and after the introduction of CT-P10 to our institute (November 2017), 221 newly-diagnosed DLBCL patients received rituximab with standard cyclophosphamide, vincristine ...

This study showed that CT-P10 has equivalent efficacy, as assessed by the proportion of patients achieving an overall response, and similar pharmacokinetics, pharmacodynamics, and safety including immunogenicity to rituximab in patients with grade 1–3a CD20-positive follicular lymphoma and a low tumour burden.

2021年9月3日 · Overall, 90% (CT-P10) and 86% (rituximab) of patients experienced treatment-emergent adverse events. Long-term safety profiles were similar between groups. Findings confirm favorable outcomes for CT-P10–treated patients with advanced-stage FL and demonstrate comparable long-term efficacy and overall safety between CT-P10 and rituximab.

2017年5月11日 · CT-P10 (Truxima™) is the first biosimilar of the reference monoclonal anti-CD20 antibody rituximab, and is approved in the EU and South Korea for the same indications as the reference drug (Table 1).

Interpretation: CT-P10 was equivalent to rituximab in terms of efficacy and was well tolerated. CT-P10 monotherapy is suggested as a new therapeutic option for patients with low-tumour-burden follicular lymphoma.

目的：本研究的目的是证明 CT-P10 与利妥昔单抗的 PK 相似性，每一种都与环磷酰胺、长春新碱和泼尼松 (CVP) 联合给药，治疗新诊断的晚期滤泡性淋巴瘤 (AFL) (NCT02162771) (Kim WS)等。 血液。 2015；126 (23)：5111）。 PK、PD、这项正在进行的研究在此展示了直至核心周期 4（12 周）的安全性和免疫原性。 方法：AFL 患者以 1:1 的比例随机接受 CT-P10 或利妥昔单抗的输注 (375mg/m 2 )，间隔 3 周，与 CVP 联合。 PK 分析根据稳态时的 AUC tau 和 C max 进行，核 …

2019年11月13日 · Conclusion: Long-term efficacy results in patients with AFL showed comparable PFS, TTP and OS between the 2 groups, indicating therapeutic similarity of CT-P10 to originator RTX. In addition, CT-P10 was consistently well tolerated and showed comparable safety profiles, including immunogenicity, over the entire study period without any ...

2016年12月2日 · CT-P10 has an identical amino acid sequence and highly similar physicochemical and in vitro functional properties to its reference drug. In patients with rheumatoid arthritis, CT-P10 has demonstrated compelling similarity in pharmacokinetics (PK), pharmacodynamics (PD), efficacy, safety and immunogenicity (Yoo DH, …

2022年11月30日 · CT-P10 (Truxima®) is a biosimilar of RTX approved by European Medicines Agency and Thai Food and Drug Administration for follicular lymphoma, diffuse large B cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, RA, granulomatosis with polyangiitis, and pemphigus vulgaris.